We developed a machine learning framework to model and evaluate splicing-relevant variant pathogenicity. We analyzed the positional distribution and potential functional effects of variants near SSs and defined six genomic regions displaying distinct mutation rates and Here we calibrate seven such tools and devise a novel tool called Splicing Clinically Applicable Pathogenicity prediction (S-CAP) that is over twice as powerful as all previous tools, removing 41% of patient VUS at 95% sensitivity. We show that S-CAP does this by using its own features and not via meta-prediction over previous tools, and that splicing pathogenicity prediction is distinct from predicting molecular splicing changes. S-CAP is an important step on the path to deriving non-coding causal diagnoses.
G enomic sequencing, and in particular exome sequencing, is revolutionizing the diagnosis of Mendelian disease 1, 2 , with over 5,000 genetic diseases already successfully mapped to over 3,000 genes 3 . Sifting through patient exomes in search of a causal variant is challenging, and variant pathogenicity prediction tools are commonly used to aid in the interpretation of variants 4 . Pathogenicity meta-predictors such as Mendelian Clinically Applicable Pathogenicity (M-CAP) 5 integrate multiple primary predictors such as combined annotation dependent depletion (CADD) 6 with cross-species sequence conservation features to offer accurate clinical-grade predictions capable of missing only a small fraction of known coding pathogenic mutations 7 . Achieving high sensitivity is important because reducing the size of the candidate list of VUS is futile if the pathogenic variant itself is incorrectly classified as benign 8 . In more complicated computational approaches, in silico pathogenicity measures are used in conjunction with phenotype-based ranking methods such as Phenomizer 9 and Phrank 10 or as a feature in variant prioritization tools such as Exomiser 11 and Automatic Mendelian Literature Evaluation (AMELIE) 12 . However, with estimates that 70% of patient cases remain undiagnosed 13, 14 , there is value in looking beyond the coding sequence. Splicing is a complex and crucial step of gene expression, wherein vast sections of RNA, called introns, are removed from a pre-messenger RNA, and the remaining RNA, called exons, are joined to form the mature mRNA. Changes in splicing induced by genetic variants can severely affect the protein-coding potential of an mRNA, such as the exclusion of an entire exon 15 or a frameshift 16, 17 induced by the creation of a new splice site (SS) 18 , among other effects [19] [20] [21] . Exome sequencing typically captures sequence information up to 50 base pairs (bp) past exon boundaries into each adjacent intron 22 . This region covers a broad class of splicing-relevant variants: those that disrupt existing SSs or exonic and proximal intronic splicing regulators and some that create new SSs.
There are over 17,000 Mendelian disease-causing variants that probably affect RNA splicing 23 . But, as we show later, a typical patient's exome contains over 500 splicing-relevant VUS, thus making it hard to consider this class of variants. Existing tools such as CADD 6 , Eigen 24 , LINSIGHT (see URLs) 25 , context-dependent tolerance score (CDTS; see URLs) 26 , and Transcript-inferred Pathogenicity (TraP) score (see URLs) 27 predict the pathogenicity of all possible variants in the genome, but in doing so they do not effectively predict splicing-relevant variant pathogenicity or provide assurances of minimizing the prediction of known pathogenic splicing-relevant variants as benign. Some methods incorporate basic splicing features: CADD includes distance to transcription start site and exon-intron boundaries; LINSIGHT includes computational prediction of changes in SS usage; and TraP includes sequencebased splicing motif disruption features. However, most methods largely ignore the rich literature characterizing RNA splicing and predicting associated molecular phenotypes, such as the 'percentage spliced in' of exons 28, 29 . The molecular splicing literature alone does not tell the whole story either, because, as we show in this study, predicting molecular effects is a fundamentally different task from predicting pathogenicity.
We introduce S-CAP (see URLs), a machine learning tool that integrates features derived from the splicing literature with measures of variant, exon, and gene importance into a splicing-specific pathogenicity score. We evaluate S-CAP at the high sensitivity required in clinical settings and show that it far outperforms existing non-coding pathogenicity scores, as well as tools focused solely on identifying synonymous variants that disrupt splicing. functional effects. We trained six models (one per region) to predict splicing variant pathogenicity. This involved building (1) a labeled data set of known pathogenic and benign splicing-relevant variants, (2) a set of features to help discriminate between the pathogenic and benign variants in each region, and (3) a learning algorithm to identify patterns in the features and to distinguish between variants in the two classes. Finally, we evaluated our models on a set of known pathogenic and benign variants, as well as on patients with various diseases caused by splicing-relevant variants and thousands of sequenced individuals from multiple ancestries.
The landscape of splice region variation. To build a data set of labeled splicing-relevant variants, we considered variant pathogenicity, semantic effect, and population frequency. We started by taking the union of 117,709 pathogenic single-nucleotide variants (SNVs) from the Human Gene Mutation Database (HGMD) 23 and 31,364 pathogenic SNVs from ClinVar 30 to obtain a total of 126,016 unique pathogenic variants. We curated 15,833,389 benign SNVs observed in controls from the Genome Aggregation Database (gnomAD) 31 , who generally do not have a Mendelian disease. To identify a subset of variants with a likely splicing semantic effect, these sets were filtered to the 'splicing region' , all synonymous or intronic variants within 50 bp 22, 32 of an exon boundary (we justify the choice of 'splicing region' further below in the text). Removing non-synonymos and loss-of-function (stop gain or stop loss) variants ensured that our model was trained and evaluated nearly exclusively on splicing-relevant variants. To avoid any ambiguities, the benign SNVs were further filtered to remove any variant labeled pathogenic in HGMD or ClinVar. This resulted in 17,165 splicingrelevant pathogenic variants and 7,027,609 splicing-relevant benign variants. Almost all known pathogenic Mendelian mutations affect far less than 1% of the population, whereas most variants observed in a patient are common, resulting in an extremely low signal-tonoise ratio among common variants, and an American College of Medical Genetics and Genomics recommendation to consider all more common variants as likely non-causative 8 . Indeed this 1% frequency cutoff removes only 106 pathogenic variants along with over a quarter of a million benign variants. These steps result in 6,760,450 rare benign splicing region variants and 17,059 rare pathogenic splicing region variants.
To substantiate that nearly all pathogenic splicing region variants do in fact disrupt splicing, we developed a simple model to assign a putative effect of variants on splicing. Variants can affect splicing by (1) creating a cryptic SS, (2) disrupting an existing SS, or (3) disrupting an existing branchpoint (BPT), a mechanistically essential sequence motif generally located 18-45 bp upstream of each 3′ SS 33 (Methods). We found that 97% of pathogenic splicing region variants are predicted to have an effect on splicing, as opposed to only 18% of likely benign variants (Fig. 1a,b) . Of the remaining variants, 41% of pathogenic variants are at conserved positions compared with only 15% of benign variants. We also found that pathogenic variants are enriched at positions where the mechanistically essential U2 small nuclear RNA (snRNA), U2 auxiliary factor, and U1 snRNA bind 34 (Fig. 1b) . In contrast, variants occurring in the general population are biased away from these positions 35 (Fig. 1a) .
Region-specific models to alleviate ascertainment bias. To capture position-specific patterns, we separated the variants into six regions relative to the SS with generally homogenous function and built a separate model for each region ( Supplementary Fig. 1 ). Specifically, we grouped variants occurring in the obligate 5′ GT (5′ core) and 3′ AG (3′ core) dinucleotide, intronic variants upstream of a 3′ SS (3′ intronic), variants lying in the canonical U1 snRNAbinding site, excluding the core 5′ SS (5′ extended) intronic variants downstream of a 5′ SS (5′ intronic), and synonymous variants within the protein-coding gene (exonic) (Fig. 1c) . During testing, we evaluated model performance separately for each region. During model training, in four of the six regions we trained our model by using data only from the specific region. However, for two of the regions, we found that there were too little data to train effectively, so we incorporated training variants from other regions (Supplementary Notes). Core SS variants are well known to have a large functional effect and are readily identified, a fact that has probably led to an overrepresentation of core SS variants in pathogenic variant databases. Around 73% of known pathogenic splicing region variants occur within the core SS (Fig. 1c) . In unbiased studies of splicing quantitative trait loci, generally fewer than 1% of splicing-relevant variants are found to be located in core SSs 36, 37 ; in a recent study using RNA sequencing (RNA-seq) data to identify splicing-relevant variants resulting in Mendelian disease, only two of six (33%) causal variants in the splicing region were in core SSs 38 . If left unaddressed, this bias would allow a classifier to have strong test set performance (by calling most core SS variants pathogenic and others benign) but would often miss non-core pathogenic SS variants. Separating variants by position allows us to ensure that pathogenic variants are rarely misclassified as benign regardless of genomic region, thereby ensuring an overall low false-negative rate irrespective of the ascertainment biases present in annotated data.
S-CAP features.
We curated existing metrics and developed several features to help distinguish between pathogenic and benign variants within the splicing region (Supplementary Table 1 ). The set consists of chromosome-, gene-, exon-, and variant-level features. At the chromosome level, three binary features distinguish among variants found on chromosome X, chromosome Y, and the autosomes. Variants on the X chromosome present an important subset, because in males, a hemizygous X chromosome variant inducing loss of function results in no viable gene product. In agreement with this intuition, pathogenic variants are highly enriched on the X chromosome compared to the autosomes (7.11-fold enrichment, P < 10 −140 by two-sided Fisher's exact test). At the gene level, pLI 35 , residual variation intolerance score (RVIS; see URLs) 39 , and a haploinsufficiency score 40 help to measure the likelihood that a given gene is a 'disease gene' . At the exon level, exon length, exon length modulo 3, reference SS strengths, an existing regional constraint score, and the exon sequence similarity between human genome 19 (hg19) and 99 species from the University of California Santa Cruz 100-way alignment serve to assist in distinguishing critical exons from those that may be safely excluded. Additionally, we developed a SS constraint score to measure the fragility and tolerance of each exon to SS mutations (Methods). At the variant level, CADD 6 measures pathogenicity on the basis of functional data annotations, LINSIGHT 25 measures variants' fitness effect through functional data and molecular evolution, and SPIDEX (see URLs) 29 was incorporated to measure the effect of a variant on exon inclusion. PhyloP 41 and PhastCons 42 scores from the multiz46way and multiz100way alignments 43 measure the evolutionary importance of the affected base across primate species, placental mammals, and all vertebrates. We also included a feature to capture the change in trimer content induced by a variant 44 . Additionally, we included region-specific features, such as a BPT disruption term for the 3′ intronic region 45 and a 5′ cryptic SS creation term for the 5′ intronic region (see Supplementary Table 1 and Methods for a complete description of features).
The machine learning algorithm. S-CAP is built by using a gradient-boosting tree (GBT) classifier, a highly effective machine learning model 46 , also used to build the M-CAP classifier 5 with its distinct feature library to predict pathogenicity for non-synonymous SNVs. The GBT model iteratively builds decision trees, wherein each tree consists of feature-based rules picked to correctly classify the majority of cases that were misclassified in the previous iteration. The final classifier is a linear combination of each of the previously derived decision trees (details in Methods).
S-CAP consistently outperforms existing pathogenicity scores.
Each of the six regions (described earlier) contains pathogenic and benign variants (Fig. 1c) , which were used to build six separate models. Eighty percent of the total data was used as a training data set, and the remaining 20% was used as a held-out test set to evaluate the final S-CAP models. Fivefold cross-validation was performed over the training data set to identify the best features and variants to be included in training for each region. Each model was then trained (on the full training data set) by using the optimally identified features and regions to create the final S-CAP models. S-CAP was evaluated against the most popular existing methods that score splicing-relevant variants-CADD 6 We built two sets of rare variants near exon boundaries that have no effect on the annotated coding sequence. a, Set of likely benign variants from gnomAD. b, Set of putatively pathogenic variants from HGMD and ClinVar. We developed a simple model to ascertain the effect of these variants on splicing, using MaxEntScan to assess whether a variant created a cryptic SS or disrupted the reference SS, and LaBranchoR in silico mutagenesis scores to assess whether a variant disrupted a BPT. In a and b, we plotted the aggregate counts of each variant set as a function of position relative to the nearest SS, colored by their putative effect. Nearly 97% of pathogenic variants in the splicing region (as defined in the text) are predicted to have a putative deleterious effect on splicing, compared with only 18% of benign variants. c, We split the variants into different regions with largely homogenous functions. Most known pathogenic variants (and the easiest ones to detect) are found in the 3′ and 5′ core SS regions, whereas most benign variants are found in the 3′ intronic, exonic, and 5′ intronic regions. In a typical (median) individual from the 1000 Genomes Project, the distribution of variants is similar to the distribution of gnomAD benign variants.
The six S-CAP models outperformed all existing methods over both the receiver operating characteristic (ROC) (Fig. 2 ) and precision-recall curve metrics in all splicing regions ( Supplementary  Fig. 2 ), with the exception of TraP in the low-sensitivity region for exonic variants. S-CAP results in up to a 30% improvement in the area under the ROC curve over the next best performing model ( Fig. 2 ) and up to a 230% improvement in the area under the precision-recall curve over the next best performing model ( Supplementary Fig. 2 ). No existing method consistently outperforms the other existing metrics across all splicing regions in either ROC (Fig. 2) or precision-recall ( Supplementary Fig. 2 ) domains. S-CAP's performance on exonic variants was also independently For each region, the corresponding model was evaluated on a set of variants (sample sizes specified in the second column of Table 3 ). For each method, 1,000 threshold points were determined by evenly spanning the range from the minimum to the maximum score observed for the method. TPRs and false positive rates (FPRs) were determined for each threshold value and used to build the ROC curve. a-f, We compared to the next best method in each region and found that S-CAP performs 9.7% better in the 3′ intronic region (a), 29.7% better in the 3′ core sites (b), 17.7% better in the exonic region (c), 28.8% better in the 5′ core sites (d), 14.9% better in the 5′ extended region (e), and 17.3% better in the 5′ intronic region (f). S-CAP outperforms existing metrics in all regions, whereas none of the existing methods consistently outperform the others. Table 2 ). We retuned each existing method separately for each of the six regions defined in Fig. 1 by finding the smallest threshold that resulted in the correct classification of 95% of pathogenic training data variants from that region. The superior S-CAP thresholds for all regions (including the dominant and recessive modes) are included in the last column. By definition, with the high-sensitivity thresholds, each method will misclassify at most 5% of known pathogenic mutations (Table 2 ), but their effectiveness at correctly classifying benign variants and reducing the number of patient VUS will vary greatly ( Fig. 3) . NA, not applicable. Each row describes a single patient, the causative gene, the underlying disease, causative variant and its zygosity, genomic coordinates of the causative variant, and the score and percentile each method assigns to the variant. The percentile was computed by measuring the fraction of variants in the same region with a score less than the score assigned to the causative variant. The ninety-ninth percentile denotes that 99% of variants in that region have a score less pathogenic than the one we are observing, thereby indicating that the variant is considered to be highly pathogenic. The entries in bold prefixed by an asterisk and the other entries in bold have the highest and second-highest percentile scores for the given variant, respectively. S-CAP ranks the causative variant most confidently in 10 of 16 cases and in the top two in 13 of 16 cases. All other methods rank the causative variant in the top in zero to two cases. Most importantly, by using our recalibrated thresholds for all tools (Table 1) , the causative variant is never misclassified by any tool. At the threshold defined by the original authors (Supplementary Table 2 ), CADD would misclassify three causative variants as benign. DDD, Deciphering Developmental Disorders project.
Technical RepoRT
NATUrE GENETiCS compared and found to be superior to that of MutPred Splice 44 , a tool focused on scoring only exonic synonymous variants (Methods and Supplementary Fig. 3 ).
Clinically relevant thresholds maintain high sensitivity. As previously advocated in M-CAP 5 , it is important to tune thresholds for clinical settings so that less than 5% of known pathogenic variants are misclassified as likely benign. LINSIGHT, Eigen, SPIDEX, and CDTS do not provide a default threshold to consider a variant as pathogenic, nor is it a simple matter to derive such a threshold, because a test set of both benign and pathogenic variants not previously available to the classifier or any of its features needs to be carefully constructed. CADD and TraP provide thresholds but, at the author-recommended default threshold, CADD incorrectly classifies virtually all (96-99%) pathogenic splicing mutations outside the two core SSs, and TraP incorrectly classifies 66-83% of pathogenic splicing mutations in 3′ intronic, exonic, and 5′ intronic regions (Supplementary Table 2 ). Similarly, MutPred Splice provides a default threshold, but over 48% of known pathogenic exonic variants are misclassified at this threshold. To improve the usefulness of these tools, we generated a high-sensitivity threshold for all metrics in each region by finding the lowest threshold that results in the correct classification of at least 95% of a test set of pathogenic variants from that region ( Table 1) .
S-CAP excels at clinically relevant thresholds. Focusing on the high-sensitivity region, at or above a 95% true positive rate (TPR), S-CAP improves on existing metrics by up to 185% ( Supplementary  Fig. 4 ). S-CAP ranged from achieving a high-sensitivity region area under the curve (hsr-AUC) of 0.235 in the 5′ intronic region ( Supplementary Fig. 4f ) to an hsr-AUC of 0.578 in the 3′ intronic region (Supplementary Fig. 4a) . Similarly, S-CAP outperformed MutPred Splice over the hsr-AUC in the high-sensitivity region on an independent test set of exonic variants by 200% ( Supplementary  Fig. 3b ). Overall, S-CAP greatly improves on existing metrics in all six splicing regions when focused on the clinically relevant highsensitivity region; no existing method consistently outperforms the others across all regions.
A framework for classifying recessive and dominant variants. Recessive and dominant diseases are associated with different selective pressure on alleles, which we hypothesized would result in different feature importance and thresholds for determining variant pathogenicity. In patients, we know whether each variant appears in the heterozygous or homozygous state. However, our training data did not provide dominant and recessive labels and our model, like all pathogenicity metrics before it, made no distinction between these cases, introducing an ambiguity that probably made it harder for our model to learn. To address this concern, we developed a framework for inferring this information from a control population for the sake of model training (Methods). We incorporated a zygosity feature to capture dominant (heterozygous in patients) and recessive (homozygous or compound heterozygous in patients) disease states at the gene level, and we identified distinct clinically relevant thresholds for each state.
Tagging 3′ and 5′ core variants as dominant or recessive resulted in improved performance compared with models without these tags. For 3′ core variants, we built a model that improved on an AUC of 0.797 and hsr-AUC of 0.256 from the original 3′ core model ( Supplementary Fig. 5a ,c) to an AUC of 0.818 and 0.862 ( Supplementary Fig. 6c,d) , and hsr-AUC of 0.270 and 0.491 ( Supplementary Fig. 6g,h ), when tested on just dominant or recessive variants, respectively. Similarly, for 5′ core variants, we built a model that improves on an AUC of 0.778 and hsr-AUC of 0.216 from the original 5′ core model ( Supplementary Fig. 5b,d ) to an AUC of 0.809 and 0.875 ( Supplementary Fig. 6a,b) , and hsr-AUC of 0.229 and 0.510 ( Supplementary Fig. 6e,f) , when testing on just dominant or recessive variants, respectively. The S-CAP model to be used on patients takes advantage of these split dominant and recessive models in the core SS regions.
S-CAP eliminates the most VUS in patient exomes.
Resources such as S-CAP are developed on large sets of known benign and pathogenic variants, but ultimately they are used to help with the interpretation of VUS in individual patients (Fig. 1c) . To demonstrate the practical utility of S-CAP, we evaluated S-CAP and each of the comparison methods on 14 patients with Mendelian diseases caused by splice-altering mutations. After application of the standard allele frequency filter of ≤1%, a typical individual has, on average, 533 rare variants within the splicing region. Typically, ~32% of variants were observed in each of the 5′ intronic, exonic, and 3′ intronic regions; 3% were in the 5′ extended regions, and less than 1% (0-3 variants) were in each of the 3′ core and 5′ core regions (Fig. 1c) . Existing methods-CADD, LINSIGHT, Eigen, SPIDEX, TraP, and CDTS-using the 95% sensitivity thresholds (Table 1) , perform comparably and on average reduce the number of VUS by 15-20%. In contrast, S-CAP reduces the number of VUS in the splicing region by 36-48% (Fig. 3c) while confidently retaining all For each of the six splicing regions, three separate models were trained and evaluated. The size of the training and testing data set for pathogenic and benign classes in each region is specified in the first and second column of the table, respectively. Columns 3-5 indicate the test set performance of a machine learning model that incorporates only the features specified in the corresponding column header. A model trained purely on the specific features of S-CAP (Supplementary Table 1 ) results in a 24% improvement in the AUC and 182% improvement in the hsr-AUC over the ROC curve over all splicing regions compared with a baseline model developed by using only preexisting metrics as features. The final S-CAP model incorporates pre-existing metrics and S-CAP-specific features and results in a 1.3% improvement in the AUC and 3.6% improvement in the hsr-AUC over the ROC curve over all splicing regions compared to the model built by using only S-CAP-specific features. Pre-existing metrics could be discarded with little loss of generality but are kept to maximize clinical utility. NR, not relevant.
pathogenic causative variants for further detailed analysis. S-CAP ranks the causative variants most confidently in 11 cases and in the top 2 in 13 of 16 cases. All other measures rank the causative variant most confidently in zero to two cases (Table 2) .
Existing pathogenicity predictors add little to S-CAP's performance.
To evaluate how much of S-CAP's performance is derived from meta-predicting over existing pathogenicity metrics versus the contribution of S-CAP's own feature set, we compared three ensemble GBT models using the following sets of features:
(1) CADD, LINSIGHT, SPIDEX, pLI, and RVIS; (2) all of S-CAP's features (Supplementary Table 1 ) except these five; and (3) all of S-CAP's features. The second model outperformed the first model in all six regions and in aggregate increased the AUC by 24% and the hsr-AUC by 182%. Adding these five existing metrics back only increased the AUC by 1.3% and the hsr-AUC by 3.6%. This finding suggests that S-CAP's features capture a novel set of splicing pathogenicity indicators not measured by existing metrics, thus resulting in improved performance (Table 3) .
Ancestry bias, HGMD versus ClinVar, training strategy, and feature contribution. S-CAP shows no bias in performance due to ancestry over rare benign variants (Supplementary Fig. 7 and Supplementary Notes) and performs similarly over the HGMD, ClinVar, and their union (Supplementary Table 3 and Supplementary Notes). The S-CAP hybrid training approach was compared with alternative training strategies to show the resulting improvement in predictive power (Supplementary Table 4 and Supplementary Notes). Finally, we also examined the contributions of the different features to S-CAP performance (Supplementary Table 5 and Supplementary Notes).
Discussion
Currently, fewer than half of suspected monogenic disease patients whose exomes are sent to be sequenced are successfully diagnosed 13, 14 . Variants affecting splicing comprise the second largest category of known pathogenic mutations 47 . A broad class of potential splicing-relevant variants is already captured by patient exome sequencing, yet clinicians are hampered in trying to interpret these variants for lack of proper predictive tools. In this study, we address this problem by developing S-CAP, a pathogenicity predictor dedicated exclusively to splicing-relevant variants. Just as in silico missense pathogenicity scores are used in conjunction with variant quality, inheritance pattern, variant frequency, and phenotypic information to prioritize missense variants, S-CAP is a clinically applicable pathogenicity score that can be incorporated into variant interpretation tools to improve splicing pathogenicity prioritization. For an in silico pathogenicity predictor to be useful in the clinic, it needs to be easy to use, carefully calibrated to high sensitivity, and capable of confidently removing a substantial fraction of benign variants. Existing tools are not easy to use for splicing variants because they lack calibration or are miscalibrated, their performance is strongly dependent on the variant's position relative to the SS (Supplementary Table 2) , and no single method consistently outperforms the others (Table 2) . We found that no existing method confidently removes a considerable fraction of benign variants (Fig. 3) . For example, after retuning (Table 1) , TraP and SPIDEX performed well on variants in the intronic bins but were close to random at distinguishing benign and pathogenic variants in core SSs. CADD, only after we retuned it (Supplementary Table 2 and Table 1 ), performed well on core and exonic variants but poorly on intronic variants (Fig. 2) . S-CAP addresses all of these important issues. It consistently outperforms existing methods across all splicing regions, its performance has been carefully evaluated at clinicalgrade sensitivity, and it removes more than twice as many benign variants as any other tested method (Fig. 3) .
Central to the design and novelty of S-CAP are: (1) using regionspecific models; (2) building a splicing-focused feature set measuring variant-and exon-level fitness; (3) splitting data at the gene level; (4) limiting training to rare variants; and (5) incorporating dominant and recessive tags. All these features aim to alleviate the effects of ascertainment biases and errors in curated pathogenic and benign variant databases. Of particular concern in splicing pathogenicity prediction is the inflated number of variants in core SSs, which exists because they are easily recognized and have well-established molecular consequences. This bias in the labeled pathogenic data can lead to unrealistic model performance, because high test set performance can be achieved by predicting that all core SS variants are pathogenic and all others are benign. However, this strategy would incorrectly classify pathogenic, non-core SS variants as benign at an unacceptably high rate. Introducing separate models for each region alleviates this concern, because each model's performance is evaluated by using data from the same region, thereby assuring high sensitivity irrespective of the underlying positional distribution of pathogenic variants. Additionally, overrepresentation of pathogenic variants in known disease-associated genes can lead to overestimated model performance, because a model can keep track of genes containing pathogenic variants during the training step and classify any variant as pathogenic if it is in a previously observed pathogenic gene. Performance on pathogenic variants in previously unassociated genes would be worse than the reported performance, because information about the previously unassociated genes was not included during model training. By ensuring that variants from the same gene were never split between the training and evaluation sets (Methods), we alleviate this concern and ensure that no gene-level information is leaked. We assumed that all variants observed in individuals from the gnomAD control database are benign in the context of Mendelian disease; however, heterozygous variants in a healthy individual may still be disease causing if found in a homozygous or compound heterozygous state in a patient. Such variants mislabeled as benign in our test data do not threaten the integrity of our model's performance, because they only deflate our reported performance. Still, we incorporated a zygosity feature to reduce this confusion and improve S-CAP performance. Because a large fraction of the sequenced individuals are of European descent, there was also concern that model performance could not be guaranteed when applied to VUS in patients from other populations. However, S-CAP was trained and evaluated by using rare benign variants, which are more family specific than ancestry-specific, and, as a result, the European bias in gnomAD does not negatively affect S-CAP performance (Supplementary Fig. 7 ).
The use of patient RNA-seq data to identify pathogenic variants that disrupt splicing is a promising field 38, 48 to which we believe S-CAP is complementary. Observing the change in percentage spliced in ΔΨ ( )of an exon through RNA-seq bypasses the difficult problem of explicitly or implicitly predicting the effect of a given variant on splicing in a particular cell type, but this answers only part of the problem. Whether predicted or measured, gene expression and Ψ values vary among cell contexts and time points, and in many cases the most relevant cell population to sequence would not be clear 48, 49 . Perhaps even more importantly, molecular phenotypes are multiple steps away from real phenotypic change, thus making it difficult to predict organismal pathogenicity from molecular phenotype 50 . Indeed, as we have shown (Fig. 1) , while 97% of known pathogenic mutations in the splicing region are predicted by a straightforward model to disrupt splicing, a full 18% of rare benign mutations (monogenic patients have 100 times more rare benign mutations than rare pathogenic mutations) are also predicted to disrupt splicing. These factors limit the direct applicability of observed or predicted ΔΨ to cases in which we understand the relationship between a disease, the cell population that it affects, and the set of potentially causative genes. Many of the features used by S-CAP, such as evolutionary conservation, exon importance, and gene haploinsufficiency, implicitly integrate an allele's importance over all cell populations and time points, complementing the strengths of RNA-seq-based methods.
Eventually, comprehensive analysis of the splicing region will become commonplace in clinical settings. There are over 500 VUS that are seldom or never observed in control populations in the splicing region per individual; identifying a causal variant among this background is complicated by the difficulty of predicting the effect of each variant on splicing and whether this change will cause disease. S-CAP represents an important step toward effectively interpreting splicing variation, increasing diagnostic yield, and growing understanding of the contribution of splicing mutations to human disease.
URLs. S-CAP scores and source code, http://bejerano.stanford.edu/ scap/ (available on publication); S-CAP codebase, https://bitbucket. org/bejerano/splicing_classifier/ (available on publication); RVIS, http://genic-intolerance.org/data/RVIS_Unpublished_ExACv2_ March2017.txt; Deep Genomics website, https://www.deepgenomics.com/; SPIDEX, http://www.openbioinformatics.org/annovar/ spidex_download_form.php/; LINSIGHT, http://compgen.cshl.edu/ ~yihuang/LINSIGHT/; TraP, http://trap-score.org/terms.jsp; CDTS, http://www.hli-opendata.com/noncoding/; LaBranchoR, http:// bejerano.stanford.edu/labranchor/; CADD, https://cadd.gs.washington. edu/; Eigen, https://xioniti01.u.hpc.mssm.edu/v1.1/; MutPred Splice, http://www.mutdb.org/mutpredsplice/about.htm; ExAC, ftp://ftp. broadinstitute.org/pub/ExAC_release/release1/regional_missense_ constraint/.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41588-019-0348-4. Variant annotation. ANNOVAR 51 version 527 was used to annotate variants with predicted effect on protein-coding genes by using gene isoforms from the Ensembl 52 gene set version 75 for the Genome Reference Consortium Human Build 37 (hg19) assembly of the human genome. All coding isoforms were used where the transcript starts, and transcript end sites were marked as complete, and the coding span was a multiple of three.
Methods
Variant filtering. All variants were filtered to only include rare variants in the splicing region that do not directly affect the protein-coding sequence. Rare variants are defined to be variants with an allele frequency of ≤1% in all control populations and subpopulations in phase 3 of the 1000 Genomes Project, ExAC version 0.3.1, and gnomAD r2.0.2. Variants in the splicing region that do not affect the protein-coding sequence are those determined to be synonymous or in the core splicing, extended splicing, or intronic regions.
A simple model for predicting the effects of variants on RNA splicing. To develop a straightforward model for predicting the effects of variants on RNA splicing, we used the existing tools MaxEntScan 53 and LaBranchoR (see URLs) 45 , which predict the strength of SS and BPT sequences, respectively. We denoted a variant as creating a cryptic SS if the variant creates a SS with a MaxEntScan score at least as high as the score for the reference SS (with the variant included), disrupting a SS if it reduces the MaxEntScan score of the reference SS by at least 1, and disrupting a BPT if it has a LaBranchoR in silico mutagenesis score of <−0.1. Additionally, we denoted variants with a PhyloP 41 score >1 as 'conserved' . In cases where a variant had multiple putative effects, for example, creating a cryptic SS and disrupting an existing SS, we resolved to the most extreme effect (cryptic SS creation > SS disruption > BPT disruption > conserved).
Positional subsetting of variants. Variants at different positions relative to SS have different properties, such as distributions of sequence conservation and ratio of pathogenic to benign variants. To better understand the relationship between position relative to SS and the mechanistic effects on splicing, we developed a simple model to assign a putative effect of variants on splicing. This led us to allocate variants into subsets according to their position relative to the SS and train separate models for each. Subsets were selected to group functionally related positions. In total, we constructed six subsets (Fig. 1) . We created subsets of 3′ and 5′ core (1 or 2 bp from the SS), extended (1-2 bp into the exon on the 5′ side and 3-6 bp from the 5′SS), 3′ intronic (2-50 bp from the SS), 5′ intronic (7-50 bp from the 5′SS), and exonic (inside the exon but outside the extended region) regions.
We associated each variant with a neighboring exon. For variants close to multiple exons, we attempted to assign the variant to the exon considered as having the highest chance of a pathogenic effect, which we inferred from the density of pathogenic variants in each bin. Specifically, we favored associations in the following order: core; 5′ extended; intronic; and exonic.
Features. Our models used a diverse library of previously described as well as new features (Supplementary Table 1 ). These can be divided into gene-, exon-, and variant-level features as well as a few features that are specific to individual regions. In the next section, we introduce such features and describe how we curated previously described features.
Gene-level features. We obtained RVIS 39 scores from the Genic Intolerance website (see URLs). We used the data in column 'RVIS[pop_maf_0.05%(any)' as a feature in our models. We obtained the pLI 35 scores from Supplementary Table 13 of the original publication. We used as a feature the column denoted as pLI. We obtained a haploinsufficiency score 40 , which is the probability of a gene being haploinsufficient, directly from the publication page on the PLoS website 40 . We also downloaded the Missense badness, PolyPhen-2, and Constraint score, a recently proposed regional constraint score 54 (see URLs).
Exon-level features. For each exon, we created SS features that measure the number of rare and common variants observed in gnomAD in the 5′ and 3′ core (0-2) and extended (2) (3) (4) (5) (6) regions. This was motivated by the desire to share information between functionally similar positions. We take this feature to represent the constraint on the exon's splicing region in the human population. To avoid data leakage, when constructing this feature for a particular variant, we masked the effect of the variant itself on this score. Specifically, if a given 5′ SS had one associated core variant, it was assigned a count of 0. If it had two, both were assigned a count of 1. Additionally, we measured exon identity across vertebrates and found that exon identities in many organisms were highly correlated.
Principal components analysis of the identity scores for all exons showed that five components explain most variation in the data. To prevent overfitting, we included the original exon identities projected onto these first five principal components as features. We also included exon length and exon length mod 3 as features associated with each variant.
Variant-level features.
To consider the local sequence context of variants, we included spectrum kernel features representing the change in trinucleotide content induced by the variant 44 . For all 64 possible trinucleotides, we created a vector counting the number of occurrences in the alternative sequence and subtracted an equivalent vector for the reference sequence. The MaxEntScan reference score, alternative score, and the difference between the two were all used as features to quantify the strength of each exon's reference and alternative 5′ and 3′ SS. SPIDEX scores 29 were downloaded directly from the Deep Genomics website (see URLs). These scores can now be downloaded from Annovar (see URLs). Any variant not assigned a SPIDEX score was assigned a value of 0. We included eight scores measuring evolutionary conservation, specifically, PhyloP 46way vertebrates, placental mammals, primates, PhyloP 100way vertebrates, phastCons 46way vertebrates, placental mammals, primates, and phastCons 100way vertebrates. Any base not annotated with a conservation score was assigned a value of 0. We also included the signed distance to the 5′ SS and 3′ SS of the associated exon as features to measure base-pair importance.
Region-specific features. The 3′ intronic S-CAP model includes a BPT feature modeled using LaBranchoR, a bidirectional long short-term memory model trained on the genome sequence surrounding experimentally validated BPT sites 45 . Specifically, we used the in silico mutagenesis scores available online (see URLs, LaBranchoR) as a feature.
We explicitly represented the strength of cryptic sites created by each variant by using MaxEntScan 53 . In 3′ intronic, 3′ core, and exonic bins, we included a 3′ cryptic SS creation term and, in the exonic, 5′ extended, 5′ core, and 5′ intronic bins, we included a 5′ cryptic SS creation term. For each variant, we scanned for the highest-scoring SS motif that overlaps the variant, excluding reference SS. We used as features the strength of the cryptic site, the change in the strength of the cryptic site induced by the variant, the distance from the reference SS to the cryptic site, and the difference in strength between the cryptic site and the reference SS.
Model training and testing. We performed fivefold cross-validation to train and identify a generalizable S-CAP model. Fivefold cross-validation refers to splitting the data into five roughly equally sized parts (folds). All variants found in a single gene were included in the same fold to ensure that there was no leakage of feature information across the training and test sets (Discussion). We then merged all five sets to form a training data set, trained the model on this training data set, and evaluated on a held-out 20% of data to obtain test accuracy. We performed this process six times (one model per region) on the held-out test set that was not included in the cross-validation training data set.
To train the S-CAP model, we used a GBT model implemented in the Python 2.7.13 sklearn version 0.18.1 library and used the default parameters to reduce the chance of overfitting the model. The average performance over fivefold crossvalidation closely resembles the performance of the held-out test set in all regions ( Supplementary Fig. 8 ).
Comparison metrics. We sought to compare our performance to those of other methods used to infer the importance/pathogenicity of non-coding variants. We evaluated the performance of each of the methods shown in this section by using the output score directly as a pathogenicity score. For SPIDEX, we negated the score, since it is consistent with large negative scores having a larger effect on function and constraint, respectively. We report performance for all subsets wherein the method reported scores for at least 50% of variants. Variants where a method did not report a score are excluded from the evaluation. CADD 6 version 1.3 scores were downloaded from the CADD website (see URLs). SPIDEX 29 scores were downloaded directly from the Deep Genomics website (see URLs). Any variant not assigned a SPIDEX score was assigned a default value of 0. LINSIGHT 25 scores were downloaded directly from the LINSIGHT website (see URLs). Any variants not assigned a LINSIGHT score was defaulted to 0. Eigen version 1.0 coding and Eigen version 1.0 non-coding 24 Phred scores were downloaded from the Eigen website (see URLs). TraP 27 scores were downloaded from TraP score website (see URLs). CDTS 26 scores were downloaded from the Human Longevity Open Data website (see URLs) and mapped into hg19 coordinates. MutPredSplice 44 scores were downloaded from the MutPredSplice website (see URLs).
As MutPred Splice was trained by using some of the same data used to build S-CAP, a random train and test split of the pathogenic data would have resulted in the inclusion of variants in the test set that were used to train the MutPred Splice classifier. To ensure zero information leakage between the training and testing data sets, we carefully built a separate test set that excluded all MutPred Splice training data.
Recessive versus dominant classifiers. We developed separate classifiers for recessive and dominant acting variants in the 3′ and 5′ core SS regions. We opted not to include dominant and recessive classifiers for the other four regions because we did not have a sufficient number of pathogenic variants to train and evaluate multiple models and, in our exploration, they made less of an impact. Intuitively, for core variants the molecular phenotype is obvious-a loss of splicing. This places the full burden on predicting whether this change will result in disease, a task heavily dependent on whether the variant acts via a recessive or dominant mechanism. Whereas in the other regions, most possible variants have little effect on splicing, thus making predictions as to whether or not the variant will have an effect on splicing is the primary challenge, a task unrelated to inheritance mode.
When evaluating a patient, core variants observed as heterozygous are routed to the dominant classifier, and variants observed to be homozygous are routed to the recessive classifier. Because there is no genotype information available for the labeled pathogenic and benign variants, we developed a framework to label variants as dominant or recessive according to their occurrence in a control population. We labeled the pathogenic variants observed as heterozygous in the control population as likely recessive because a single copy can apparently be tolerated with no major issues, and pathogenic variants never observed in the control population are likely to be dominant. Benign heterozygous variants that are never observed as homozygous in the healthy control population provide less information regarding their potential to cause a recessive-acting disease. In this case, we tagged benign heterozygous variants never observed to be homozygous as dominant, and benign variants observed as homozygous as recessive. Additionally, because any variant on the X chromosome resembles a homozygous autosomal variant in males, all X chromosome variants were tagged as recessive.
We encoded whether each variant was considered dominant or recessive as a binary feature and trained a single GBT model for each region. Then, we found two 95% TPR thresholds separately on the basis of test sets of only dominant-tagged and only recessive-tagged variants.
Patient data sets. Sequencing and diagnosis for all patients was performed by other laboratories. All patient data were downloaded by requesting access to the European Genome-phenome Archive and the database of Genotype and Phenotype. Variant call files for 11 patients were submitted by the Deciphering Developmental Disorders project in the European Genome-phenome Archive study (EGAS00001000775). An additional three patient variant call files were submitted to the database of Genotypes and Phenotypes (study phs000655.v3.p1).
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Code availability
The S-CAP code is publiclally available at Bitbucket (see URLs) for noncommercial purposes.
Data availability
S-CAP scores for all rare variants in the predefined splicing region in the human genome, along with the source code repository, training and test set variant IDs, and final trained models for the S-CAP classifier, will be made available via the S-CAP website on publication.
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